Editorial on “Chinese expert consensus on the clinical practice of non-small cell lung cancer fusion gene detection based on RNA-based NGS” (2023 edition)

References

[1] NCCN. NCCN clinical practice guidelines in oncology: non–small cell lung cancer, version 3. 2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl_harmonized-vietnam.pdf [Last accessed on 20 Feb 2024].

[2] The Society of Cancer Precision Medicine of Chinese Anti-Cancer Association; China Primary Health Care Foundation Tumor Precision Diagnosis and Treatment Committee; Chinese Anti-Cancer Association, Lung Cancer Study Group of Committee of Oncopathology. [Chinese expert consensus on the clinical practice of non-small cell lung cancer fusion gene detection based on RNA-based NGS].Zhongguo Fei Ai Za Zhi2023;26:801-12.

[3] Davies KD,Lawrence CA.DNA-based versus rna-based detection of MET exon 14 skipping events in lung cancer.J Thorac Oncol2019;14:737-41

[4] Claerhout S,Vander Borght S.Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.Lung Cancer2022;166:242-9

[5] Ritterhouse LL.Targeted RNA sequencing in non-small cell lung cancer.J Mol Diagn2019;21:183-5

[6] Seto K,Fujita S.Targeted RNA sequencing with touch imprint cytology samples for non-small cell lung cancer patients.Thorac Cancer2020;11:1827-34 PMCID:PMC7327906

[7] Heyer EE,Wooi D.Diagnosis of fusion genes using targeted RNA sequencing.Nat Commun2019;10:1388 PMCID:PMC6437215

[8] Shaw AT,Bang YJ.Crizotinib in ROS1-rearranged non-small-cell lung cancer.N Engl J Med2014;371:1963-71

[9] Shaw AT,Bang YJ.Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.Ann Oncol2019;30:1121-6 PMCID:PMC6637370

[10] Paik PK,Veillon R.Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations.N Engl J Med2020;383:931-43

[11] Cohen D,Solleveld-Westerink N.Optimizing mutation and fusion detection in NSCLC by sequential DNA and RNA sequencing.J Thorac Oncol2020;15:1000-14

[12] Li W,Guo L.Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer.BMC Med2022;20:160 PMCID:PMC9087946

[13] Yang SR,Rosen EY.A performance comparison of commonly used assays to detect RET fusions.Clin Cancer Res2021;27:1316-28 PMCID:PMC8285056

[14] Xiang C,Zhao R.Identification and validation of noncanonical RET fusions in non-small-cell lung cancer through DNA and RNA sequencing.J Mol Diagn2022;24:374-85

[15] Drilon A,Han JY.Clinicopathologic features and response to therapy of NRG1 fusion-driven lung cancers: the eNRGy1 global multicenter registry.J Clin Oncol2021;39:2791-802

[16] Drilon A,Mangatt BP.Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers.Cancer Discov2018;8:686-95 PMCID:PMC5984717

[17] Strohmeier S,Popper H,Lindenmann J.Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma.Sci Rep2021;11:9785 PMCID:PMC8105314

[18] Kulda V,Svaton M.Next generation sequencing analysis and its benefit for targeted therapy of lung adenocarcinoma.Cancer Genomics Proteomics2023;20:404-11 PMCID:PMC10320561

[19] Vingiani A,Conca E.Pan-TRK immunohistochemistry as screening tool for NTRK fusions: a diagnostic workflow for the identification of positive patients in clinical practice.Cancer Biomark2023;38:301-9